In short
This article discusses the ongoing clinical trials of NX210c, a synthetic peptide drug being studied as a potential treatment for Amyotrophic Lateral Sclerosis (ALS). The trials aim to assess the drug's efficacy, safety, tolerability, and pharmacokinetics in adult patients with ALS. The study focuses on evaluating the effects of NX210c on various biomarkers, functional capacities, and disease progression in ALS patients.
At a glance
- Drug Name
- NX210c (H-L-Tryphophanyl-L-Seryl-Glycyl-L-Tryptophanyl-L-Seryl-L-Seryl-L-Cysteinyl-L-Seryl-L-Arginyl-L-Seryl-L-Cysteinyl-Glycyl-Oh (Disulfide Bond), Acetate Salt)
- Trial Phase
- Phase II
- Condition Studied
- Amyotrophic Lateral Sclerosis (ALS)
- Main Objectives
- Assess effects on blood NfL and blood-brain barrier integrity biomarkers
- Secondary Objectives
- Evaluate effects on functional capacities, disease progression, survival, and quality of life
- Administration
- Intravenous infusions
- Maximum Dose
- 10 mg/kg daily, 120 mg/kg total over 4 months
- Key Measurements
- Blood and CSF biomarkers, ALSFRS-R, SVC, muscle strength, disease progression rate, quality of life
- Eligibility
- Adults with ALS diagnosis, disease duration ≤36 months, specific lung function capacity
What is NX210c?
NX210c is a new medication being studied for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. It is a synthetic peptide, which means it's a small protein-like molecule created in a laboratory. The full chemical name of NX210c is quite complex: H-L-TRYPHOPHANYL-L-SERYL-GLYCYL-L-TRYPTOPHANYL-L-SERYL-L-SERYL-L-CYSTEINYL-L-SERYL-L-ARGINYL-L-SERYL-L-CYSTEINYL-GLYCYL-OH (DISULFIDE BOND), ACETATE SALT.
Purpose of the Study
Researchers are conducting a Phase II clinical trial to evaluate how well NX210c works and how safe it is for people with ALS. This study, called SEALS (Safety and Efficacy of ALS Study), aims to determine if NX210c can help slow down the progression of ALS and improve the quality of life for patients.
How NX210c Works
While the exact mechanism is not fully explained in the study details, NX210c is designed to target certain aspects of ALS. The researchers are particularly interested in its effects on: Neurofilament light chain (NfL): A protein that can be measured in blood and spinal fluid, which may indicate the rate of nerve cell damage. Blood-Brain Barrier (BBB) integrity: The BBB is a protective barrier that separates the brain from the bloodstream. In ALS, this barrier may be compromised. Neuroinflammation: Inflammation in the nervous system, which is thought to play a role in ALS progression. Neuronal and synaptic transmission: How nerve cells communicate with each other, which is affected in ALS.
Eligibility Criteria
To participate in this study, patients must meet certain criteria, including: Be 18 years or older Have a diagnosis of ALS according to specific criteria Have had ALS symptoms for 36 months or less Have a certain level of lung function (measured by something called Slow Vital Capacity or SVC) There are also several conditions that would prevent someone from participating, such as certain medical conditions or recent participation in other drug trials.
Study Objectives
The main goals of this study are to: Measure the effect of NX210c on neurofilament light chain levels in blood and spinal fluid Assess how NX210c affects the integrity of the blood-brain barrier Evaluate the impact of NX210c on ALS symptoms and disease progression Determine if NX210c affects survival in ALS patients Assess the safety and tolerability of NX210c
Potential Benefits
If successful, NX210c could potentially: Slow down the progression of ALS Improve functional capacities in ALS patients Enhance the quality of life for people living with ALS Potentially extend survival time for ALS patients However, it's important to note that these potential benefits are still being studied and are not guaranteed.
Safety and Side Effects
As with any new medication, safety is a crucial concern. The study will closely monitor for any side effects or adverse reactions to NX210c. Participants will undergo regular check-ups, including physical examinations, blood tests, and other assessments to ensure their safety throughout the trial.
It's important to remember that NX210c is still in the research phase. While it shows promise, more studies are needed to fully understand its effectiveness and safety profile in treating ALS.